Predicting Treatment Response in Esophagogastric Cancer Patients
Author Information
Author(s): Nixon Andrew B., Navarro Fábio C. P., Zhou Katherine I., Abbott Charles, McDaniel Lee, Howard Lauren, Brady J Christopher, Liu Yingmiao, Jia Jingquan, Niedzwiecki Donna, Strickler John, Boyle Sean M., Chen Richard O., Uronis Hope
Hypothesis
Can ultra-sensitive ctDNA profiling predict treatment response and disease progression in esophagogastric cancer patients?
Conclusion
Ultra-sensitive ctDNA profiling can predict treatment responses and detect disease progression earlier than traditional imaging methods.
Supporting Evidence
- All 25 patients evaluated were ctDNA-positive at baseline.
- ctDNA dynamics were highly correlated with changes in tumor size.
- Lack of early molecular response was associated with worse overall survival.
- Molecular progression preceded imaging-derived progression by a median lead time of 65 days.
Takeaway
This study shows that a special blood test can help doctors know if cancer treatment is working or if the cancer is getting worse, even before scans can tell.
Methodology
The study used an ultra-sensitive liquid biopsy platform to analyze ctDNA from patients in a clinical trial.
Participant Demographics
Patients with metastatic esophagogastric cancer receiving chemotherapy and immunotherapy.
Statistical Information
P-Value
p = 0.005
Confidence Interval
95% CI 1.8-24.1
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website